StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

StockNews.com downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a report released on Tuesday morning.

Several other equities research analysts have also recently commented on REGN. Royal Bank of Canada reissued an outperform rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Truist Financial reaffirmed a buy rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a report on Wednesday, March 13th. UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a buy rating in a report on Wednesday, April 17th. Finally, Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $890.66 on Tuesday. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock has a 50 day simple moving average of $945.77 and a 200-day simple moving average of $895.19. The company has a market cap of $97.76 billion, a PE ratio of 25.63, a P/E/G ratio of 2.54 and a beta of 0.11. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the previous year, the company earned $10.96 earnings per share. The firm’s quarterly revenue was up .6% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 38.8 EPS for the current year.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold a total of 10,195 shares of company stock worth $9,759,898 in the last ninety days. Corporate insiders own 8.83% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. West Paces Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. MCF Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $37,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.